Nazan Akpolat/iStock via Getty Images BioRestorative Therapies ( NASDAQ: BRTX ) traded ~20% higher in the premarket Thursday after the New York-based biotech said it has engaged in talks with a commercial-stage company to license IP rights related to its ThermoStem platform. Without naming its potential partner, BioRestorative ( BRTX ) said that the company held “substantive” discussions with a commercial-stage regenerative medicine company for a possible deal, ThermoStem represents BioRestorative’s ( BRTX ) metabolic program, designed to develop cell therapy candidates based on brown adipose (fat)- derived stem cells (BADSCs). Studies have shown the potential of BADSCs in treating obesity and related metabolic disorders.
“It has been captivating to watch the scale, scope, and speed with which potential license partners have begun to show interest in our proprietary off-the-shelf ThermoStem® platform,” said Lance Alstodt, BRTX’s CEO. More on BioRestorative Therapies BioRestorative Therapies, Inc. (BRTX) Q1 2024 Earnings Call Transcript BioRestorative Therapies receives Nasdaq notice of non-compliance BioRestorative gains as FDA clears amendment to study on cell therapy candidate Seeking Alpha’s Quant Rating on BioRestorative Therapies Historical earnings data for BioRestorative Therapies.
